Company: IMNN
Filing Date: 2025-07-22
Form Type: 8-K
Source: 0001641172-25-020520
Chunk: 0

Company: Imunon, Inc.
Filing Date: 2025-07-22
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events.

On
July 22, 2025, Imunon, Inc. (the “ Company”) filed a prospectus supplement (the “ Prospectus Supplement”)
to register an additional $4,500,000 of shares (the “ Shares”) of the Company’s common stock, par value
$0.01 per share (“ Common Stock”), issuable pursuant to the At the Market Offering Agreement, dated as of May 25, 2022, as
amended by Amendment No. 1 to At the Market Offering Agreement, dated as of May 15, 2024 (as amended, the “ Sales Agreement”),
by and between the Company and H. C. Wainwright & Co., LLC, as sales agent or principal (the “ Sales Agent”). The Company
previously registered the offer and sale of up to $5,500,000 of shares of Common Stock through the Sales Agent under the Sales Agreement.
Accordingly, the Prospectus Supplement covers an aggregate of $10,000,000 of Shares. Of such amount, prior to the date hereof, the Company has sold an aggregate of $1,815,267 shares of Common Stock through the Sales Agent
under the Sales Agreement. An opinion
regarding the legality of the Shares issuable under the Sales Agreement and covered by the Prospectus Supplement is filed as Exhibit
5.1 to this Current Report on Form 8-K.

Item
9.01. Financial Statements and Exhibits.

(d)
Exhibits

  Exhibit      Description                                                             
      No.                                                                              
 ───────────────────────────────────────────────────────────────────────────────────────
      5.1      Opinion of Thompson Hine LLP.                                           
     23.1      Consent of Thompson Hine LLP (included in Exhibit 5.1).                 
      104      Cover                                                                   

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                     IMUNON,                                       
  Dated:             By:          /s/                              
                                  Susan                            
                                  General